Maybe it’s overdramatizing to say it feels like we’re passing through history, but as a number of Bay Area biopharma companies approach the cusp of drug approvals, it feels like we may not pass this way again.
It’s something to consider as the state’s biomedical industry players meet this week for the CalBio 2012 conference in San Francisco.
Maybe it’s my limited experience, but the sheer volume of drugs from Bay Area companies that are in front of the FDA in early 2012 seems unprecedented. After watching capital dry up for four years, just getting to this point seems a victory for some companies.
But for today's small life sciences companies to deliver big-time drugs in the coming years will take a new model for funding.